DDrare: Database of Drug Development for Rare Diseases

Searched query = "Porphyria", "CEP", "Erythropoietic protoporphyria", "EPP", "X-linked dominant protoporphyria", "XLDP", "PCT", "HEP", "AIP", "ADP", "VP", "Hereditary coproporphyria", "HCP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 1639325-43-1; 5-probe cocktail; A novel synthetic, orally-administered, non-peptide small molecule, which acts as; ALN-60519; ALN-AS1; Afamelanotide; Afamelanotide Implant; CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid); CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid); COLESTYRAMINE; CUV1647; Chlorpromazine; Chlorpromazine Hydrochloride; Colestipol; Colestyramine; Concentration unit: mg milligram(s); Cysteine; Cysteine hydrochloride; Deferasirox; Dersimelagon; Exjade; Givosiran; Givosiran (ALN-AS1); Glucose; Harvoni; Heme arginate; Hemin; Hemin for injection; Hydroxychloroquine; Iron; Isoniazid; Luteinizing hormone; Luteinizing hormone-releasing factor; MT-7117; MT-7117 High Dose; MT-7117 Low Dose; MT-7117 high dose; MT-7117 low dose; Nle4-D-Phe7-alpha-MSH; Oral Iron; Other: Glucose; Panhematin; Porphobilinogen; Procedure: Phlebotomy; Questran; Recombinant human porphobilinogen deaminase (Porphozym); SCENESSE; Scenesse; Sterile Normal Saline (0.9% NaCl); Tin mesoporphyrin; [MT-7117]; [Nle4,D-Phe7]-a-melanocyte stimulating hormone or NDP-a-MSH

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02979249 (ClinicalTrials.gov)	December 2016	29/11/2016	Oral Iron for Erythropoietic Protoporphyrias	Effect of Oral Iron Therapy on Erythrocyte Protoporphyrin Levels in the Erythropoietic Protoporphyrias	Erythropoietic Protoporphyria;EPP;X-linked Protoporphyria;XLP	Drug: Oral Iron	Icahn School of Medicine at Mount Sinai	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	18 Years	N/A	All	16	N/A	United States
2	NCT01284946 (ClinicalTrials.gov)	January 2011	26/1/2011	Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda	A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload	Porphyria Cutanea Tarda	Drug: Exjade	Assistance Publique - Hôpitaux de Paris	Association pour l'Etude des Fonctions Digestives (AEFD)	Recruiting	18 Years	N/A	Both	45	Phase 2	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02979249
(ClinicalTrials.gov)

December 2016

29/11/2016

Oral Iron for Erythropoietic Protoporphyrias

Effect of Oral Iron Therapy on Erythrocyte Protoporphyrin Levels in the Erythropoietic Protoporphyrias

Erythropoietic Protoporphyria;EPP;X-linked Protoporphyria;XLP

Drug: Oral Iron

Icahn School of Medicine at Mount Sinai

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

18 Years

N/A

All

N/A

United States

NCT01284946
(ClinicalTrials.gov)

January 2011

26/1/2011

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload

Porphyria Cutanea Tarda

Drug: Exjade

Assistance Publique - Hôpitaux de Paris

Association pour l'Etude des Fonctions Digestives (AEFD)

Recruiting

18 Years

N/A

Both

Phase 2

France